SLAMF7 and Miyoshi myopathy: Several antigens that exhibit strong expression in MM cells, including CD38, CD138, CD56, CD74, CD40, insulin-like growth factor-1 receptor (IGF-1R), signaling lymphocyte activating-molecule F7 (SLAMF7), and immunoglobulin superfamily member FcRL5, may be candidates for antibody-related immunotherapy [178].